Synmosa Biopharma Corporation (TPEX:4114)

Market Cap	15.00B
Revenue (ttm)	5.55B
Net Income (ttm)	684.68M
Shares Out	455.25M
EPS (ttm)	1.62
PE Ratio	20.34
Forward PE	n/a
Dividend	0.55 (1.67%)
Ex-Dividend Date	Aug 9, 2024

Volume	445,013
Average Volume	483,238
Open	33.10
Previous Close	32.95
Day's Range	32.90 - 33.25
52-Week Range	28.90 - 38.35
Beta	-0.02
RSI	58.88
Earnings Date	May 8, 2025

About Synmosa Biopharma

Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches, develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand name in Taiwan. The company offers its products in various therapeutic areas, including cardiovascular, respiratory, urology, sex hormone, and oncology. The company also provides its products in various forms, such as effervescent tablets, granules, nasal sprays, metered dosed inhalers, sex hormones, and other forms. In addition, it offers contract manufact...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1980
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4114

Financial Performance

In 2024, Synmosa Biopharma's revenue was 5.55 billion, an increase of 7.96% compared to the previous year's 5.14 billion. Earnings were 684.68 million, an increase of 15.11%.